Comparing Escalation and Induction Therapy in Patients Over 50 with Early-Onset Multiple Sclerosis

What this Trial Is About

This observational study focuses on patients diagnosed with relapsing-remitting multiple sclerosis RRMS who had their first symptoms after age 50. Researchers aim to evaluate the risk of inflammatory disease activity by comparing two therapeutic approaches escalation therapy and induction therapy. The study also seeks to identify factors linked to inflammation relapse and complications related to treatment. The trial is sponsored by the University Hospital in Strasbourg, France. The study compares two treatment strategies involving disease-modifying antirheumatic drugs DMARDs. One group receives moderately effective DMARDs such as teriflunomide, dimethyl fumarate or diroximel fumarate, glatiramer acetate, interferon beta, or peginterferon. The other group receives highly effective DMARDs, including fingolimod, ponesimod, natalizumab, rituximab, ocrelizumab, ofatumumab, or cladribine. Participants started their first therapy within two years of symptom onset. Participants will be observed for up to 12 months to measure the time until the first clinical inflammatory relapse. Researchers will review medical histories and analyze treatment-related outcomes. The study does not involve administering treatments but collects data retrospectively. This approach helps to understand disease activity and treatment effects in patients with late-onset MS.

Escalation vs. Induction Therapy Strategy in Patients With Early-Onset MS After Age 50